July 23, 2016
Recommended Topic Related To:


"Chronic itch, which occurs in many medical conditions and in response to certain drugs, affects millions of Americans, yet its causes are poorly understood. Now, investigators funded in part by the NIH's National Institute of Arthritis and Muscul"...



Side Effects


Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

In two clinical trials, 1227 subjects were treated with JUBLIA, 1161 for at least 24 weeks and 780 for 48 weeks. Adverse reactions reported within 48 weeks of treatment and in at least 1% of subjects treated with JUBLIA and those reported in subjects treated with the vehicle are presented in Table 1.

Table 1: Advers e Reactions Reported by at Leas t 1% of Subjects Treated for up to 48 Weeks

Adverse Event, n (%) JUBLIA
N = 1227
N = 413
Ingrown toenail 28 (2.3%) 3 (0.7%)
Application site dermatitis 27 (2.2%) 1 (0.2%)
Application site vesicles 20 (1.6%) 0 (0.0%)
Application site pain 13 (1.1%) 1 (0.2%)

Read the Jublia (efinaconazole topical solution) Side Effects Center for a complete guide to possible side effects


In vitro studies have shown that JUBLIA, at therapeutic concentrations, neither inhibits nor induces cytochrome P450 (CYP450) enzymes.

This monograph has been modified to include the generic and brand name in many instances.

Last reviewed on RxList: 7/21/2016

Side Effects

Report Problems to the Food and Drug Administration


You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

Women's Health

Find out what women really need.